Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

Stopped Difficulties with enrollment and inability to guarantee further study drug supply after current supply expired.

Conditions

• Clostridia Difficile Colitis
• Clostridium; Sepsis

Interventions

• BIOLOGICAL: Bezlotoxumab
• OTHER: Normal Saline

Sponsor

Michael E Villarreal, MD

Collaborators

• [object Object]